STAT+: Johnson & Johnson advances IBD therapy, despite trial miss
A closely watched therapy developed by Johnson & Johnson failed to show a statistically meaningful improvement for IBD patients.
Original Source
Read the full article at Statnews →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.